Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism – Yahoo Finance

NEW YORK, Nov. 29, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an original article titled: “Oral Insulin (ORMD-0801) in Type 2 Diabetes Mellitus: Dose-Finding 12-Week Randomized Placebo-Controlled Study,” authored by Roy Eldor, MD PhD, Bruce H. Francis, MD, Alexander Fleming, MD, Joel Neutel, MD, Kenneth Homer, MS, Miriam Kidron, PhD, and Julio Rosenstock, MD.
 
The article presents the results of a 12-week multicenter, randomized, placebo-controlled trial assessing the safety and efficacy of multiple active doses of Oramed’s lead drug candidate ORMD-0801 in patients with uncontrolled Type 2 Diabetes (T2DM) on chronic background therapy with Metformin or combination oral therapy. The trial met the primary endpoint of statistically significant reductions of HbA1c from baseline to Week 12. In addition, the treatment doses were safe, well tolerated and not associated with weight gain or hypoglycemia.
“This paper presents interesting and important results of Oramed’s Phase 2 dose ranging study of oral insulin. Based on the results of this study, a bedtime dose of 8 mg is being carried forward into the Phase 3 registration studies,” said Roy Eldor, MD PhD, Director, Diabetes Unit, Institute of Endocrinology, Metabolism & Hypertension, Tel-Aviv Sourasky Medical Center, and a member of Oramed’s Scientific Advisory Board.
The article can be accessed on Oramed’s website under Scientific Articles and Abstracts.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq: ORMP) (TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
For more information, please visit www.oramed.com.
Forward-looking statements:  This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the plans for Phase 3 registration studies, as well as the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed’ s reports filed from time to time with the Securities and Exchange Commission.
Logo – https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg
Company Contact:
Zach Herschfus
+1-844-9-ORAMED
zach@oramed.com
View original content:https://www.prnewswire.com/news-releases/oramed-announces-publication-of-oral-insulin-study-in-peer-reviewed-journal-diabetes-obesity-and-metabolism-301688925.html
SOURCE Oramed Pharmaceuticals Inc.
Related Quotes
Shares of Novocure (NASDAQ: NVCR) were jumping 7.6% higher as of 10:42 a.m. ET on Tuesday. The nice gain came after the company announced that Health Canada approved Optune for treating newly diagnosed and recurrent glioblastoma (GBM), an aggressive form of brain cancer. Canada represents a significant market opportunity for Novocure.
Matt Cardona will compete in a high-stakes tag team match […] The post Matt Cardona, KiLynn King, And More Announced For 11/29 NWA Powerrr appeared first on Wrestlezone.
Arrowhead provided a bullish update for its midstage liver disease treatment on Monday, pushing ARWR stock to rocket Tuesday.
A new study found that Eisai and Biogen's experimental Alzheimer’s drug moderately reduced cognitive decline after a year and a half.
Axsome's (AXSM) phase III ACCORD study evaluating AXS-05 for treating Alzheimer's disease agitation met the primary and key secondary endpoints. Shares rise.
Biogen stock was muted late Tuesday after Eisai unveiled Alzheimer's treatment results likely to spark a debate over the drug's benefits.
Japan's Eisai , which is developing the treatment with the U.S. pharmaceutical company, said in a September press release that the therapy worked surprisingly well.
The drugmaker recently had a market value almost $18 billion as big pharmaceutical companies rely on acquisitions to expand sales.
The drug from Eisai and Biogen slowed cognitive decline in study volunteers, but many had brain bleeds, swelling or other side effects.
The new stores will occupy approximately 3,000 square feet, less than a third of the size of a standard Rite Aid Pharmacy.
(Bloomberg) — Horizon Therapeutics Plc soared in post-market US trading after the developer of medicines for rare autoimmune and inflammatory diseases said it’s in talks with a trio of potential suitors about a possible sale of the company.Most Read from BloombergScientists Revive 48,500-Year-Old ‘Zombie Virus’ Buried in IceBanks Stuck With $42 Billion Debt Seize Chance to Offload ItThese Are the Best and Worst Cities for Expats to Live and Work InThis Is Where Luxury Property Prices May Rise a
OPKO Health (OPK) is likely to gain from the potential in RAYALDEE that targets a growing market coupled with new collaborations and acquisitions.
Is Merck stock a buy after the company announced its acquisition of Imago, a bone marrow diseases company? Is MRK stock a buy now?
Eisai plans to share additional data about the Alzheimer’s disease treatment it's developing with Biogen this week.
Is Pfizer stock a buy after surging on Moderna's omicron-focused booster shot data? Is PFE stock a buy right now?
Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.
Spectrum (SPPI) gets a CRL from the FDA for poziotinib as the agency requires additional data. The company de-prioritized the poziotinib program.
(Bloomberg) — Eisai Co shares fell the most in about 16 months following a report of a second death potentially linked to the groundbreaking experimental drug for Alzheimer’s disease it’s developing with Biogen Inc.Most Read from BloombergApple to Lose 6 Million iPhone Pros From Tumult at China PlantNext Covid-19 Strain May be More Dangerous, Lab Study ShowsMusk Threatens War With Apple, Jeopardizing Vital RelationshipStocks Hit by Fedspeak as China Woes Boost Havens: Markets WrapThe case invol
Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher.
Palforzia, the world’s only approved peanut allergy drug, has so far proved a flop, potentially because of a laborious treatment process.

source